Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Cash from Investing Activities: 2020-2025

Historic Cash from Investing Activities for Caribou Biosciences (CRBU) over the last 5 years, with Sep 2025 value amounting to $10.9 million.

  • Caribou Biosciences' Cash from Investing Activities fell 59.09% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.2 million, marking a year-over-year increase of 155.59%. This contributed to the annual value of $86.6 million for FY2024, which is 227.02% up from last year.
  • As of Q3 2025, Caribou Biosciences' Cash from Investing Activities stood at $10.9 million, which was down 54.86% from $24.0 million recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' Cash from Investing Activities registered a high of $49.4 million during Q1 2025, and its lowest value of -$174.0 million during Q4 2021.
  • Moreover, its 3-year median value for Cash from Investing Activities was $20.7 million (2023), whereas its average is $9.3 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first tumbled by 327,659.09% in 2022, then spiked by 179.18% in 2023.
  • Caribou Biosciences' Cash from Investing Activities (Quarterly) stood at -$174.0 million in 2021, then soared by 100.67% to $1.2 million in 2022, then crashed by 2,790.09% to -$31.5 million in 2023, then spiked by 150.61% to $15.9 million in 2024, then plummeted by 59.09% to $10.9 million in 2025.
  • Its Cash from Investing Activities was $10.9 million in Q3 2025, compared to $24.0 million in Q2 2025 and $49.4 million in Q1 2025.